Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
نویسندگان
چکیده
منابع مشابه
Presumed Isotretinoin-Induced, Concomitant Autoimmune Thyroid Disease and Ocular Myasthenia Gravis: A Case Report
INTRODUCTION There are many adverse effects that have been described for isotretinoin. To the best of our knowledge, this is the first report of a possible association of oral isotretinoin intake with autoimmune thyroiditis and ocular myasthenia gravis (OMG). CASE PRESENTATION A 19-year-old Caucasian male, who had used oral isotretinoin for severe acne disease for the previous six months, was...
متن کاملEmergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
Dear Editor, A 34-year-old woman presented with a 4-week history of diplopia, dysphagia, and dyspnea. She had no previous history of a neuromuscular disorder. However, she had been diagnosed with thymic cancer (squamous cell carcinoma) 2 years previously, with metastasis to the pericardium, pleura, and lung, which had not been successfully treated with conventional chemotherapy (cyclophosphamid...
متن کاملMyasthenia gravis and sevoflurane--a case report.
Myasthenia gravis is characterized by weakness and easy fatiguability of voluntary muscles. Myasthenic patients are sensitive to non-depolarizing relaxants. Sevoflurane, as an alternative, can be used to achieve good tracheal intubation. In this report, we present our experiences.
متن کاملMyasthenia gravis and atracurium. A case report.
The degree, duration of and recovery from neuromuscular blockade induced by atracurium in a patient with myasthenia gravis were monitored and recorded using the evoked compound muscle action potentials (EMG). The anaesthetic and perioperative management were simplified by the use of this technique. The significance of the behaviour of atracurium is discussed.
متن کاملMyasthenia Gravis Induced by Nivolumab: A Case Report
Nivolumab is a programmed cell death receptor (PD-1) inhibitor therapy for aggressive cancers; however, it poses a risk of immune-related adverse side effects. We present a 73-year-old male with renal cell carcinoma who developed myasthenia gravis (MG) after being treated with nivolumab, proven by acetylcholine receptor antibodies. Our patient presented with symptoms of fatigue and upper and lo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Medical Case Reports
سال: 2021
ISSN: 1752-1947
DOI: 10.1186/s13256-021-02722-8